Inspired by our findings on the cytostatic and cytotoxic impact of type I IFN signaling on AML blasts and LSCs, we moved to determine the prognostic role of type I IFN genes in AML patients from Study Cohort 1 (n = 132) (Table 1), upon stratifying the entire patient cohort based median IFNA1, IFNA2, IFNB1 expression level or median IFN-i values into IFNLo (n = 66) and IFNHi (n = 66) groups. The gene discussed is IFNB1; the disease is acute myeloid leukemia.